First Major Clinical Trial of an Oral Agent Inducing ApoA-1 Synthesis: A New Approach to Raising HDL and CV Risk Modification - ASSERT


The goal of the trial was to compare treatment with the oral inducer of apoA-1 synthesis, RVX-208, compared with placebo among statin-treated patients with stable coronary artery disease (CAD).